Evidence map›Paper›PMID 39520579›Full record

ArticleMedical microbiology and immunology2024

Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses.

Fangfang Chang, Qian Wu, Yabin Hu, Zhendong Pan, Yong-Chen Liu, Yue-Zhou Li, Mihnea Bostina, Wenpei Liu, Ping Zhao, Xiaowang Qu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical microbiology and immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fangfang Chang *Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Qian Wu *Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Yabin HuTranslational Medicine Institute, Hengyang Medical School, The First People's Hospital of Chenzhou, University of South China, Chenzhou, China.
Zhendong PanDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China.
Yong-Chen LiuInstitute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Yue-Zhou LiInstitute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Mihnea BostinaDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Wenpei LiuCollege of Basic Medical Sciences, Hengyang Medical School, University of South China & MOE Key Lab of Rare Pediatric Diseases, Hengyang, China.
Ping ZhaoDepartment of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China. pnzhao@163.com.
Xiaowang QuCollege of Basic Medical Sciences, Hengyang Medical School, University of South China & MOE Key Lab of Rare Pediatric Diseases, Hengyang, China. quxiaowang@163.com.
Yi-Ping LiInstitute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. lyiping@mail.sysu.edu.cn.

Funding

Advancing Knowledge for the Clinical and Public Health Response to the 2019-nCoV Epidemic' from the European Commission 101003562
6 · The paper itself

Abstract

The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig). A bsAb 5-HI showed a high binding capability to the S1 subunit of spike and exhibited breadth and potency against pseudotyped SARS-CoV-2 variants of concerns (VOCs) and SARS-related-CoVs (SARSr-CoVs), with half maximal effective concentration (EC

Indexed as

Antibodies, BispecificAntibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsHumansNeutralization TestsProtein EngineeringSevere acute respiratory syndrome-related coronavirusAntibodies, BispecificAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2bi-specific antibody (bsAb)monoclonal antibody (mAb)SARS-CoV-2SARSr-CoVsvariants of concerns (VOCs)

Identifiers

PMID39520579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.